Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Personalized Medicine

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795811

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795811

Companion Diagnostic Tests in Oncology

PUBLISHED:
PAGES: 501 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Companion Diagnostic Tests in Oncology Market to Reach US$10.0 Billion by 2030

The global market for Companion Diagnostic Tests in Oncology estimated at US$6.3 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Protein Detection-Immunohistochemistry, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the DNA Detection-Polymerase Chain Reaction segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 12.4% CAGR

The Companion Diagnostic Tests in Oncology market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Companion Diagnostic Tests in Oncology Market - Key Trends & Drivers Summarized

Why Are Companion Diagnostic Tests Revolutionizing Cancer Treatment Worldwide?

Companion diagnostic tests in oncology are fundamentally transforming how cancers are detected, classified, and treated by aligning specific therapies with individual patient profiles. These tests identify biomarkers that predict a patient’s response to a targeted therapy, making treatment more precise, effective, and personalized. Unlike conventional diagnostic approaches, companion diagnostics allow clinicians to match patients with the therapies most likely to benefit them while avoiding ineffective or potentially harmful treatments. This represents a major shift in oncology from a one-size-fits-all model to a precision medicine approach. As cancer types become increasingly segmented by genetic mutations and molecular signatures, these diagnostics are becoming indispensable in guiding therapeutic decisions. For instance, tests that detect HER2 expression in breast cancer or EGFR mutations in non-small cell lung cancer help determine eligibility for specific biologics or tyrosine kinase inhibitors. The clinical value of such testing is particularly high in cancers with well-defined genetic drivers, where outcomes are closely tied to molecular profiles. As pharmaceutical companies develop more targeted oncology drugs, the co-development of companion diagnostics is emerging as a standard strategy to gain regulatory approval and improve clinical trial success rates. The integration of these tests into early-stage cancer management is also facilitating timely intervention, improving prognosis, and enhancing patient quality of life. This confluence of clinical, economic, and technological benefits is positioning companion diagnostic tests as essential tools in the modern oncology care continuum.

How Are Technological Innovations Driving Advancements in Companion Diagnostics?

Technological innovation is playing a pivotal role in enhancing the accuracy, speed, and utility of companion diagnostic tests in oncology. Advances in genomic sequencing, especially next-generation sequencing (NGS), have revolutionized how multiple cancer-related mutations can be identified from a single sample. This capability has made it feasible to develop multiplexed assays that screen for various actionable biomarkers simultaneously, providing a more comprehensive understanding of the tumor’s molecular landscape. Additionally, the emergence of liquid biopsy technology is enabling non-invasive testing through blood or other bodily fluids, eliminating the need for tissue biopsies in many cases and allowing for easier monitoring of treatment response and disease progression. Machine learning and artificial intelligence are being incorporated into companion diagnostic platforms to analyze complex genomic data, detect patterns, and generate actionable insights that support clinical decision-making. Digital pathology and imaging techniques are also contributing to improved biomarker identification by integrating visual data with molecular profiles. Furthermore, automation in laboratory workflows is increasing throughput, reducing error rates, and shortening turnaround times, making these tests more accessible to clinicians and patients. Companion diagnostics are now being integrated into digital health platforms and electronic medical records, facilitating seamless coordination between diagnostic labs, oncologists, and treatment centers. These technological advances are not only improving test sensitivity and specificity but are also expanding the range of detectable biomarkers across cancer types. As innovation accelerates, companion diagnostic tests are becoming more scalable and cost-effective, supporting their integration into routine oncology practice on a global scale.

What Market and Regulatory Trends Are Shaping the Growth of Companion Diagnostics in Oncology?

The growth of the companion diagnostic market in oncology is being shaped by dynamic shifts in regulatory policy, payer reimbursement, and collaborative commercialization strategies. Regulatory agencies such as the FDA, EMA, and PMDA are increasingly recognizing the critical role of companion diagnostics in therapeutic decision-making and have established frameworks for co-approval of drugs and their corresponding diagnostic tests. These parallel approval pathways are encouraging pharmaceutical and diagnostics companies to engage in early-stage partnerships, integrating biomarker development into the drug discovery process. Reimbursement policies are evolving to support broader test accessibility, especially as health systems begin to recognize the long-term cost savings associated with precision medicine approaches that reduce treatment failure rates and adverse effects. Value-based healthcare models are emphasizing clinical utility, requiring that diagnostics demonstrate clear benefit in guiding treatment and improving outcomes. In response, diagnostic developers are investing in real-world evidence studies and health economics analyses to strengthen their value proposition to payers and providers. Intellectual property and data-sharing agreements are also becoming central to industry collaborations, as stakeholders seek to balance innovation with affordability and data interoperability. Market competition is intensifying, with both large in vitro diagnostic firms and smaller molecular diagnostics startups racing to develop biomarker panels for a growing list of targeted therapies. In parallel, governments and healthcare institutions are launching precision oncology initiatives to expand access to genomic testing and build national databases that support biomarker research. These regulatory and market forces are collectively creating a more favorable environment for the expansion of companion diagnostics, especially in high-incidence cancers and advanced therapeutic areas.

What Factors Are Driving the Global Demand for Companion Diagnostic Tests in Oncology?

The growth in the companion diagnostic tests in oncology market is driven by a convergence of clinical, technological, demographic, and commercial factors that reflect the evolving landscape of cancer treatment. The increasing global cancer burden, particularly the rising incidence of solid tumors and hematologic malignancies, is creating a strong demand for diagnostics that can personalize therapy and improve treatment outcomes. As cancer care shifts toward targeted and immunotherapies, companion diagnostics are becoming essential for identifying the right patients for the right treatments, thereby enhancing efficacy and minimizing toxicity. Growing awareness among oncologists and patients about precision medicine is accelerating test adoption, particularly in developed markets with advanced healthcare infrastructure. The expanding pipeline of targeted oncology drugs, many of which require biomarker validation for regulatory approval, is fueling the co-development of companion diagnostics. Pharmaceutical companies are investing in partnerships with diagnostics firms to improve clinical trial enrollment and align drug launches with diagnostic readiness. Technological advancements such as NGS, AI-based analytics, and digital health integration are making diagnostics faster, more accurate, and easier to deploy. Government support for precision medicine initiatives and favorable reimbursement trends are further contributing to market growth. Additionally, the proliferation of molecular testing laboratories and the decentralization of diagnostic services are making companion diagnostics more accessible in emerging markets. As healthcare systems worldwide strive for more personalized, data-driven approaches to cancer care, companion diagnostic tests are emerging as indispensable tools that bridge the gap between molecular insights and therapeutic decisions. These factors collectively underscore the rapid expansion of this market and its central role in the future of oncology.

SCOPE OF STUDY:

The report analyzes the Companion Diagnostic Tests in Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Detection Technique (Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization, Other Detection Techniques); Biomarker (EGFR Biomarker, KRAS Biomarker, HER2 Biomarker, BRAF V600E Biomarker, Other Biomarkers); Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma, Other Cancer Types); End-User (Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • Agilent Technologies
  • Almac Group
  • ARUP Laboratories
  • bioMerieux
  • Bio-Rad aboratories
  • Caris Life Sciences
  • Danaher Corporation
  • Exact Sciences Corporation
  • Foundation Medicine
  • Guardant Health
  • Illumina
  • Invitae Corporation
  • Myriad Genetics
  • NeoGenomics Laboratories
  • Qiagen
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Veracyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38648

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Companion Diagnostic Tests in Oncology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted Cancer Therapies Propels Growth in Companion Diagnostic Development
    • Precision Medicine Initiatives Expand Addressable Market for Tumor-Specific Diagnostic Platforms
    • Biomarker Discovery Advancements Throw the Spotlight on Next-Generation Sequencing-Based CDx Solutions
    • Immuno-Oncology Pipeline Growth Accelerates Demand for Predictive Companion Diagnostics
    • Liquid Biopsy and Minimally Invasive Testing Trends Spur Innovation in Blood-Based Companion Diagnostics
    • Rising Incidence of Solid Tumors and Rare Cancers Generates Demand for Indication-Specific CDx Tests
    • Clinical Trial Complexity Drives Uptake of Companion Diagnostics in Patient Stratification Strategies
    • Global Harmonization of Regulatory Pathways Supports Cross-Border Launch of CDx-Linked Therapies
    • Data-Driven Oncology Platforms Propel Growth in AI-Supported and Integrated CDx Solutions
    • Pharma Investment in Personalized Oncology Strategies Sustains Long-Term Demand for CDx Collaborations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Companion Diagnostic Tests in Oncology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Protein Detection-Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Protein Detection-Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Protein Detection-Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for DNA Detection-Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for DNA Detection-Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for DNA Detection-Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Next-Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for In-Situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for In-Situ Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Detection Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Detection Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Detection Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for EGFR Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for EGFR Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for EGFR Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for KRAS Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for KRAS Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for KRAS Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for HER2 Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for HER2 Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for HER2 Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for BRAF V600E Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for BRAF V600E Biomarker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for BRAF V600E Biomarker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 59: World Recent Past, Current & Future Analysis for Diagnostic Labs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: World Historic Review for Diagnostic Labs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: World 16-Year Perspective for Diagnostic Labs End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 62: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 65: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 71: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: USA Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 74: USA Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: USA Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: USA 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 83: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Canada Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 86: Canada Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Canada Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Canada 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 95: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Japan Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 98: Japan Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Japan Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Japan 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 101: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 110: China Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: China Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: China 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 128: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: France 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Germany 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Italy 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 164: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 173: UK Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: UK 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 185: Spain Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Spain Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Spain 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 194: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Russia Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 197: Russia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Russia Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Russia 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Europe Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Europe 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 233: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Australia Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 236: Australia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Australia Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Australia 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 239: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 245: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: India Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 248: India Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: India Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: India 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 257: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: South Korea Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 260: South Korea Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: South Korea Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: South Korea 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Rest of Asia-Pacific Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Rest of Asia-Pacific 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 284: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Latin America Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 287: Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Latin America Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 296: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Argentina Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 299: Argentina Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Argentina Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Argentina 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 308: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Brazil Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 311: Brazil Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Brazil Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Brazil 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 320: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Mexico Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 323: Mexico Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Mexico Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Mexico 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 334: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Rest of Latin America Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 337: Rest of Latin America 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 340: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 343: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 346: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 347: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Middle East Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 349: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 350: Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Middle East Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 352: Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 355: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 358: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 359: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Iran Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 361: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 362: Iran Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Iran Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 364: Iran 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 367: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 370: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 371: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Israel Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 373: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 374: Israel Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Israel Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 376: Israel 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 385: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Saudi Arabia Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 388: Saudi Arabia 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 391: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 394: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 395: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: UAE Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 397: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 398: UAE Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: UAE Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 400: UAE 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 409: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Rest of Middle East Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 412: Rest of Middle East 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Companion Diagnostic Tests in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Companion Diagnostic Tests in Oncology by Detection Technique - Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 415: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by Detection Technique - Percentage Breakdown of Value Sales for Protein Detection-Immunohistochemistry, DNA Detection-Polymerase Chain Reaction, Next-Generation Sequencing, In-Situ Hybridization and Other Detection Techniques for the Years 2014, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Companion Diagnostic Tests in Oncology by Biomarker - Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 418: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by Biomarker - Percentage Breakdown of Value Sales for Other Biomarkers, EGFR Biomarker, KRAS Biomarker, HER2 Biomarker and BRAF V600E Biomarker for the Years 2014, 2025 & 2030
    • TABLE 419: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Africa Historic Review for Companion Diagnostic Tests in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 421: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, Melanoma and Other Cancer Types for the Years 2014, 2025 & 2030
    • TABLE 422: Africa Recent Past, Current & Future Analysis for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Africa Historic Review for Companion Diagnostic Tests in Oncology by End-user - Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 424: Africa 16-Year Perspective for Companion Diagnostic Tests in Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Diagnostic Labs End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!